ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

15,723Medicare Part D Prescriptions Filled, Including Refills

Rank: 32 out of 384

$386K Total Retail Price of All Prescriptions

Rank: 86 out of 384

354 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
1% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Puerto Rico
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 13,662 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$25 was the average price of a prescription from this provider, compared to $45 among peers.

Prescriptions per Patient

44 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Puerto Rico
LISINOPRIL 1,132 996 1 14
LOVASTATIN 1,034 934 2 80
METFORMIN HCL 995 909 3 2
AMLODIPINE BESYLATE 922 846 4 3
LEVOTHYROXINE SODIUM 889 795 5 11
GABAPENTIN 834 722 6 4
LOSARTAN POTASSIUM 740 636 7 5
PRAVASTATIN SODIUM 653 547 8 24
LOSARTAN-HYDROCHLOROTHIAZIDE 428 387 9 10
METOPROLOL TARTRATE 393 336 10 15
ATORVASTATIN CALCIUM 384 326 11 22
ALENDRONATE SODIUM 358 329 12 20
RANITIDINE HCL 357 302 13 7
OMEPRAZOLE 337 293 14 8
ATENOLOL 281 246 15 12
PENTOXIFYLLINE 244 212 16 113
GLIMEPIRIDE 233 226 17 18
GLIPIZIDE 231 181 18 27
HYDROCHLOROTHIAZIDE 180 159 19 16
ASPIRIN EC 178 136 20 31
GLYBURIDE 166 150 R 21 82
TRAMADOL HCL-ACETAMINOPHEN 157 119 22 13
BUMETANIDE 145 135 23 195
DOXAZOSIN MESYLATE 143 133 24 29
EVISTA 141 119 25 52
FENOFIBRATE 114 103 26 53
CARVEDILOL 113 79 27 23
HUMULIN N 109 93 28 57
LYRICA 108 102 29 92
CILOSTAZOL 106 103 30 70
ETODOLAC 102 85 31 101
ISOSORBIDE MONONITRATE ER 98 94 32 28
TAMSULOSIN HCL 90 63 33 25
VERAPAMIL ER 87 68 34 41
DICLOFENAC POTASSIUM 86 77 35 38
CLOPIDOGREL 84 74 36 30
INSULIN SYRINGE 79 56 37 46
FUROSEMIDE 77 54 38 17
SURE COMFORT 69 49 39 96
ISOSORBIDE DINITRATE 69 42 39 118
AZITHROMYCIN 68 53 41 59
PLAVIX 67 56 42 32
TRAMADOL HCL 67 62 42 40
BACLOFEN 62 52 44 109
DONEPEZIL HCL 62 62 44 33
ENALAPRIL MALEATE 60 51 46 6
AMLODIPINE BESYLATE-BENAZEPRIL 59 42 47 43
DIGOXIN 57 46 48 49
MECLIZINE HCL 57 57 48 73
HUMALOG MIX 75-25 55 48 50 104
RAMIPRIL 53 49 51 51
CALTRATE 600 + D 53 40 51 196
CRESTOR 53 46 51 45
CIPROFLOXACIN HCL 51 46 54 50
ASPIR-LOW 50 46 55 176
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 17, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.